Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. by Righi, L et al.
 
 
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 [Annals of oncology, 21 (3), 2010, DOI 10.1093/annonc/mdp334] 
 ovvero [Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, 
Pelosi G, Rindi G, Papotti M., 21 (3),Oxford University Press , 2010, pagg.548-555] 
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
[http://annonc.oxfordjournals.org/content/21/3/548.long] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Original article 
 
Somatostatin Receptor tissue distribution in lung neuroendocrine tumours: a 
clinicopathologic and immunohistochemical study of 218 “clinically aggressive” cases. 
 
Luisella Righi
1
, Marco Volante
1
, Veronica Tavaglione
1
, Andrea Billè
2
, Lorenzo Daniele
3
, 
Tiziana Angusti
4
, Frediano Inzani
5
, Giuseppe Pelosi
6
, Guido Rindi
5
, Mauro Papotti
1
  
 
1
Divisions of Pathology, 
2
Thoracic Surgery and 
4
Nuclear Medicine, Department of Clinical & 
Biological Sciences, University of Turin at San Luigi Hospital, Orbassano, Italy, 
3
Department of 
Biomedical Sciences & Human Oncology, University of Turin, Torino; 
5
Division of Pathology, 
University of Parma, Parma; 
6
Diagnostic Histopathology Unit, European Institute of Oncology and 
University of Milan, Milano, Italy.  
 
Address for correspondence: Luisella Righi, MD, Department of Clinical & Biological 
Sciences, University of Turin at San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, 
Torino, Italy. Tel: +390119026018; Fax +390119026753; E-mail: luisella.righi@unito.it 
 
 3 
SUMMARY 
 
Background. The management of pulmonary neuroendocrine tumours, with special reference to 
clinically aggressive carcinoids and large cell neuroendocrine carcinomas, is poorly standardized 
and data about somatostatin receptor expression or therapeutic guidelines for somatostatin analog 
administration are still debated.  
Patient and methods. A series of 218 lung neuroendocrine tumours (24 metastatic typical 
carcinoids, 73 atypical carcinoids, 60 large cell neuroendocrine carcinomas and 61 surgically 
resected small cell carcinomas) was investigated for somatostatin receptor types 2A and 3 tissue 
distribution using immunohistochemistry, in correlation with clinicopathologic parameters, 
outcome, scintigraphy and treatment.  
Results. Somatostatin receptors were heterogeneously distributed with a significant progressive 
decrease from low to high grade forms. Somatostatin receptor type 2A was strikingly over-
expressed in metastatic typical carcinoids as compared to atypical carcinoids and clinically benign 
typical carcinoids. Somatostatin receptor tissue immunolocalization correlated with octreotide 
scintigraphy in 20/28 cases.  
Conclusions. The immunohistochemical determination of somatostatin receptors, with special 
reference to low/intermediate grade tumors, may assist the clinical approach with somatostatin 
analog-based diagnostic and therapeutic procedures in clinically aggressive pulmonary 
neuroendocrine tumors.  
 
KEY WORDS: carcinoid, immunohistochemistry, lung, neuroendocrine tumours, scintigraphy, 
somatostatin receptor. 
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INTRODUCTION 
 
 Neuroendocrine tumours (NETs) are neoplasms mainly originating from the gastro-entero-
pancreatic area (67.5%) and the bronchial tree (25.3%) [1]. According to the World Health 
Organization (WHO) criteria [2], lung tumours with neuroendocrine morphology include four major 
categories of morphologically identifiable NETs from low (typical carcinoid, TC) and intermediate 
grade (atypical carcinoid, AC), to high grade tumours (large cell neuroendocrine carcinoma, 
LCNEC, and small cell carcinoma, SCLC) that exhibit considerably different histological and 
clinical characteristics [3]. TCs are generally benign tumours with an excellent prognosis after 
radical surgery (up to 98% of 5-year survival). Regional lymph node or distant metastases are 
detected or develop over time in about 10% of cases. ACs are histologically similar to TCs (though 
with a higher mitotic count and/or necrosis), but up to 48% of cases present lymph node or distant 
metastases at diagnosis; their prognosis has been related to several predictive factors [4]. LCNEC 
and SCLC, both highly aggressive tumours, have overlapping histopathological features (except for 
the cell size) and clinical behaviour [5, 6]. 
Several neuroendocrine markers and hormonal receptors have been described in NETs 
having diagnostic, prognostic and also therapeutic implications. Among the latter, somatostatin 
receptors (SSTRs) are a  family of five widely distributed G-protein-coupled receptors, that mediate 
different intracellular signalling pathways involved in cell proliferation, differentiation and 
angiogenesis [7]. Synthetic somatostatin analogs have been produced, being octreotide and 
lanreotide those most widely employed in the clinical practice. Their high receptor binding affinity 
(especially for SSTR2, SSTR3 and SSTR5) [8] is the basis for both diagnostic (i.e. scintigraphy or 
PET scans) and therapeutic procedure. Novel ligands with enhanced and/or wide receptor affinity 
(for example multivalent ligands, such as pasireotide) are currently under validation [9]. 
Differently from gastro-entero-pancreatic NETs, the management of pulmonary NET affected 
patients is less standardized apart from surgical resection [10], chemo-radiotherapy or liver 
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metastasis embolization [11]. In particular, diagnostic and therapeutic guidelines for somatostatin 
analog use in lung NETs are not available and their association with standard chemotherapy is still 
debated [12]. This may in part be due to the incomplete knowledge on SSTR(s) expression and 
distribution in pulmonary NETs: data so far generated have generally been based on polymerase 
chain reaction, in situ hybridization, autoradiography or immunohistochemistry analyses of limited 
and/or heterogeneous neuroendocrine tumour series, accounting for less than 100 reported cases 
(most of them being carcinoids) [13-20]. Recently, we reported a strong correlation between 
specific cellular patterns of SSTR2 immunostaining and in vivo scintigraphic data in a large series 
of gastro-entero-pancreatic and few lung neuroendocrine tumours [21], indicating that 
immunohistochemistry may correctly define the SSTR protein distribution in these neoplasms.  
Since in the common clinical practice the presence of one or more SSTR subtypes in a given 
tumour (either by means of positive somatostatin analog-based nuclear imaging or SSTR 
immunohistochemistry) should be demonstrated to justify patient’s selection for somatostatin 
analog therapy, this study was aimed at correlating the SSTR expression profile of a large series of 
“clinically aggressive” pulmonary neuroendocrine tumours (thus excluding conventional non-
metastatizing typical carcinoids) with complete clinical and pathological data in order to 
substantiate the rationale for somatostatin analog clinical use in these tumour categories.  
 
MATERIALS AND METHODS 
 
Case series 
 In years 1989-2007, a total of 883 cases of surgically resected NETs of the lung were on 
record in the pathology files of the Universities of Turin and Parma and at the IEO of Milan (467, 
188 and 228 cases, respectively). Among them, a series of 218 “clinically aggressive” lesions was 
collected (129 cases from Turin, 40 from Parma and 49 from Milan) that included 24 TC with 
metastases at the time of diagnosis (TC mets) [all but one in regional lymph nodes, the remaining 
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case to the liver], 73 AC, 60 LCNEC and 61 surgically resected SCLC. For all cases, from one to 
six representative haematoxylin and eosin sections were available for review and re-classification 
according to the WHO scheme [2]. A control group of 41 TC free from node and distant metastases 
at the time of diagnosis and during available follow up (control TC) were collected from the files of 
the University of Turin, in the same period. 
 Pathological material corresponded to primary lung samples in all but 14 cases, where 
lymph node metastases only were analyzed. For all cases, clinicopathologic information including 
sex, age, tumour location, surgical procedure, parenchymal location, primary tumour size, Ki-67 
labeling index (expressed as the percentage of positive cells in highest labeling areas), nodal status, 
stage, follow up and site of distant metastases were collected. All cases were anonymized by a 
pathology staff member not involved in the study. Clinical data were compared and analysed 
through coded data, only. The study was approved by the institutional review board of the Hospital. 
In 28 cases, [
111
In-DTPA
0
]-octreotide scintigraphic data (Octreoscan) were available for 
correlation analyses (eight of these cases had been included in a previous report [19]). Somatostatin 
receptor scintigraphy findings were scored into four groups, according to Kwekkeboom et al [22] 
criteria.  
Finally, eight cases were submitted to somatostatin analog based therapy (intramuscular 
injection of octreotide for six months, 20 mg/28 days, and/or 90Y-DOTATOC radiometabolic 
therapy, either alone or in combination with chemotherapeutic agents) and information on response 
to treatment (in terms of partial remission, stable disease or progressive disease) were available.  
 
SSTR immunohistochemistry 
 Immunohistochemistry was performed using polyclonal antibodies against SSTR type 2A, 
(diluted 1/3000, BioTrend Cologne, Germany), type 3 (diluted 1/1000, AbCam, Cambridge, UK) 
and type 5 (diluted 1/500, AbCam) according to previously described protocols [21]. The specificity 
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of the reactions was validated in parallel control sections stained by omitting the primary antibodies 
for each immunohistochemical run. Pancreatic islets served as positive controls.  
The efficiency of all three antibodies was tested in a pilot series of 56 randomly selected 
cases. SSTR5 immunohistochemistry in positive controls and test sections proved unsatisfactory in 
terms of both intensity and background, and was therefore not investigated further in the whole 
series. 
 
SSTR2A and SSTR3 staining evaluation 
Immunohistochemical stains for SSTR type 2A and type 3 were scored as recently proposed 
by our group [21]. This semi-quantitative scoring system applies better for SSTR2A and takes into 
consideration both the subcellular localization and the extent of the staining, as follows: score 0: 
absence of immunoreactivity; score 1: pure cytoplasmic immunoreactivity, either focal or diffuse; 
score 2: membranous reactivity in less than 50% of tumour cells, irrespective of the presence of 
cytoplasmic staining; score 3: circumferential membranous reactivity in more than 50% of tumour 
cells, irrespective of the presence of cytoplasmic staining. 
SSTR3 immunohistochemical reaction showed a diffuse cytoplasmic staining, with weak 
membrane reinforcement in some cases, either of control or of test series. Reactions were evaluated 
in a four-tier scoring system, from 0 (no reaction) to 3, according to the intensity of cytoplasmic 
staining and irrespective of the extent of positive neoplastic cells.  
 
Statistical analysis 
For statistical purposes, immunohistochemical scores 2 and 3 of both SSTR type 2A and 
type 3 antibody were grouped together and considered positive, while scores 0 and 1 were 
considered negative. Chi-square and One-way ANOVA tests were used to compare 
clinicopathologic data and SSTR(s) distribution among different tumour categories, setting the level 
of statistical significance of p=0.05. Concondance analysis between immunohistochemical results 
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and scintigraphy data was investigated using a contingency table analysis. Univariate survival 
analysis among different tumour categories and with respect to SSTR(s) expression was based on 
the Kaplan-Meier product limit estimate of overall survival distribution. Unadjusted differences 
between survival curves were tested using the LogRank test. 
 
RESULTS  
 
Clinicopathologic findings  
Clinicopathologic features of the 218 cases of “clinically aggressive” lung NETs are 
summarized in Table 1. 
Male predominance was observed in high grade carcinomas as opposed to low and 
intermediate grade tumours (p<0.0001), whereas no significant difference among the different 
tumour types was observed in terms of patient age, tumour location and surgical procedure applied. 
With respect to pulmonary location, a significant difference was observed among the four 
groups (p=0.02), being central location predominant in TC mets, as compared to AC and LCNEC 
which presented a more frequent peripheral onset, whereas SCLC were equally distributed among 
the two locations. 
The mean primary tumour size significantly increased from TC mets to AC and poorly 
differentiated tumours (p=0.003), as well as the mean Ki-67 proliferative index (p<0.0001). The 
rate of nodal involvement at the time of diagnosis was 47%, 39% and 61% in AC, LCNEC and 
SCLC respectively, with no difference between N1 vs N2-3 location of positive lymph nodes.  
Overall survival was strongly depending on tumour type (Figure 1, p<0.0001) with no 
disease-related deaths for the metastatic TC group, and a mean overall survival of 122, 30 and 23 
months for AC, LCNEC and SCLC, respectively. 
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With respect to the presence of ectopic peptide secretion, all cases were clinically non-
functioning, except for two cases of AC with ectopic ACTH secretion in the presence of diabetes 
mellitus and metabolic disorders.  
 
Immunohistochemical distribution of SSTR2A and SSTR3 
All immunohistochemical reactions were analyzed independently by two observers (LR and 
MV) in one centre (Turin) according to the previously described scoring system. A satisfactory 
reproducibility was obtained in the vast majority of cases and the few discrepant cases were re-
scored at a multi-head microscope and a consensus was reached. SSTR2A staining pattern showed a 
strong membrane positivity in TC mets and AC groups as opposed to high grade carcinoma groups, 
in which membrane staining was found in focal areas or scattered cells only (Figure 2A). SSTR3 
showed cytoplasmic reactivity with different staining intensity and only rare cases showed a 
membrane pattern of staining. SSTR types 2A and 3 distribution among the different tumour types 
is illustrated in Figure 2B. SSTR type 2A was expressed in 34% of control TC, 71% of metastatic 
TC, 51% of AC, 33% of LCNEC and 38% of SCLC. Similarly, SSTR type 3 showed a progressive 
decrease of positive reaction from low to intermediate to high grade tumour cases, being 
significantly expressed  in 66% of control TC, 58% of metastatic TC, 45% of AC, 33% of LCNEC 
and 29% of SCLC. Grouping together low/intermediate grade (TC mets and AC) and high grade 
cases (LCNEC and SCLC) the difference of SSTR2A and SSTR3 expression was 56% vs 36% and 
48% vs 31%, respectively (Figure 2B). 
Detailed analysis of SSTR type 2A and type 3 immunohistochemical distribution in 
correlation with the different tumour types (Table 2) revealed a significantly higher expression of 
both SSTR2A and SSTR3, either alone or in combination, in the low to intermediate grade tumour 
group (TC mets + AC) as compared to high grade carcinomas (LCNEC + SCLC). Comparing the 
different groups individually, TC mets showed a significantly higher expression as compared to 
control (non metastatic) TC, in terms of both SSTR2A expression alone and in the presence of 
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SSTR2A and SSTR3 co-expression. The prevalence of SSTR2A expression in TC mets was also 
higher as compared to AC, although just below statistical significance. AC showed a significantly 
higher prevalence of SSTR2A expression and SSTR2A/SSTR3 co-expression as compared to 
LCNEC, and a lower expression of SSTR3 as compared to control TC. Interestingly, similar results 
for both SSTR2A and SSTR3 expression prevalence were observed in LCNEC and SCLC groups.  
 
Correlation between SSTR2A and SSTR3 immunohistochemistry with clinicopathologic 
parameters. 
No significant correlation was found in the group of either low and intermediate grade 
tumors (TC mets + AC) or high grade carcinomas (LCNEC + SCLC) tumours correlating SSTR2A 
and SSTR3 expression with clinical and pathological parameters, except for a higher prevalence of 
SSTR3 positive cases in the N+ group (without distinction of N1 or N2-3 lymph node station) of 
poorly differentiated carcinomas (p=0.01). No association with clinical behaviour and outcome was 
observed for SSTR(s) expression in any tumour type. Furthermore, no correlation was observed 
between mean Ki-67 and SSTR(s) expression evaluated within each tumour category  (data not 
shown).  
 
Correlation between SSTR2A and SSTR3 immunohistochemistry with in vivo octreotide 
scintigraphy data.  
In 28 cases, octreotide scintigraphy data were available either performed pre-operatively or, 
most often, post-operatively when a metastatic event occurred. Comparing the scintigraphy data 
with SSTR(s) immunohistochemistry, an overall SSTR2A immunohistochemistry/octreotide 
scintigraphy agreement of 64% (18/28 cases) was reached. Different concordance rates were 
observed in the group of low and intermediate grade tumours (69%) and poorly differentiated 
carcinomas (40%). Correlation of SSTR3 antibody reactivity with in vivo data was less striking with 
an overall agreement of 50%. The immunohistochemical presence of at least one receptor type was 
 12 
concordant with scintigraphy in 20/28 cases (71% of agreement), although with a marked loss of 
“specificity” (Table 3). 
With respect to biotherapy response, 8 cases, all but one affected by AC, received at the time 
of disease progression long-acting octreotide and/or therapy with radiolabeled octreotide, both 
associated or not to standard platinum-based chemotherapy. SSTR2A immunoreactivity correlated 
with response to treatment in all but one cases (7/8); among these, three patients had disease 
stabilization in the presence of SSTR2A expression, whereas the remaining four cases, completely 
lacking SSTR2A reactivity, had disease progression. The single discrepant case had disease 
progression in spite of SSTR2A immunohistochemical expression. Notably, octreotide scintigraphy 
correlated with somatostatin analog response in 50% of cases (4/8), only. 
 
DISCUSSION 
 
In the present study, we analyzed the tissue distribution of SSTR2A and SSTR3 in a large 
series of pulmonary neuroendocrine neoplasms consisting of low to intermediate grade tumours 
with “clinically aggressive” features (i.e. lymph node or distant metastases) and high grade large 
cell or small cell carcinomas. Although the link between SSTR(s) expression and lung NETs 
management was already proposed [7, 23], an extensive analysis of SSTR tissue distribution is 
missing, being data available for limited series, with heterogeneous techniques and mostly restricted 
to clinically benign carcinoids (usually not requiring further treatment) [13, 14, 18, 19].  
From the literature data, the current knowledge on SSTRs and lung NETs can be 
summarized as follows: i) lung NETs contain SSTR subtypes having an affinity to octreotide, 
namely types 2, 3 and 5, with a decreasing expression from low/intermediate to high grade tumours 
[23]; ii) somatostatin receptor scintigraphy may be used to localize neuroendocrine tumours primary 
or secondary to the lung [24], although its role is supported by limited literature data, most often 
biased by heterogeneous imaging modalities, small case series and unselected tumour types [25, 
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26]; iii) biotherapies with somatostatin analogs are largely employed for advanced NETs of the 
gastro-entero-pancreatic tract, either alone or in combination with interferon or chemotherapeutic 
agents [12], but in lung NETs the experience is restricted to limited clinical studies using 
somatostatin analogs as drugs [11, 27] or radionuclide vectors [28]. In summary, compared to 
gastro-entero-pancreatic NETs, the management of aggressive forms of lung NETs is not well 
clarified yet and the role of biotherapies is incompletely explored.  
In this study, a complete map of SSTR type 2A and type 3 tissue distribution was provided 
in a large series of lung NETs including the whole spectrum of clinically aggressive forms (from 
metastatic typical carcinoids to small cell lung cancer).   
Both SSTR types 2A and 3 had a decreased expression from low/intermediate to high grade 
tumours, as previously observed by our group in smaller series [18, 19]. Interestingly, in the group 
of low to intermediate grade tumours, SSTR2A was expressed at a significant higher frequency in 
metastatic TC as compared either to clinically benign control TCs, alone (p=0.004) or in co-
expression with SSTR3 (p=0.04), either compared to the AC group. The Ki-67 index of TC with 
metastases was not different from that of non metastatic TC (data not shown), suggesting that the 
SSTR2A status rather than the proliferation fraction is related to metastatic propensity in lung 
carcinoids. Furthermore, a higher expression of intracellular molecules downstream to the SSTRs, 
such as mTOR and its effector p70S6K, was observed by our group in a series of metastatic TC as 
compared to non-metastatizing TC (manuscript in preparation), further supporting a biological 
diversity among these two subgroups.  No data on the functional role of somatostatin receptors in 
favouring tumor metastases are present in the literature that might support this observation, that 
apparently contrasts with the decrease of somatostatin receptor expression in high grade – 
frequently metastatic - tumors and whose biological meaning would need further investigation. 
Moreover, it should be underlined that our series of metastatic TC had an excellent prognosis since 
no patient (even the single case with liver metastases) is currently dead of the disease, thus 
confirming that nodal involvement in typical carcinoids is not significantly impacting on survival 
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(aggiungere citazione Ferolla) and raising the question of the potential clinical benefit of post-
surgical somatostatin analog therapy in asymptomatic patients. 
When comparing the present immunohistochemical results with the prevalence data of 
positive octreotide scintigraphy in lung NETs available from the literature, a slightly higher 
percentage is reported  for carcinoids (about 70% of primary tumours in one of the most recent and 
complete series – 28 cases) [29], while an exceedingly higher  percentage is reported for SCLC, (up 
to 96% of primary tumours in a large, old series – 100 cases) [30]. In the present series of 28 cases 
with available scintigraphy data, an overall 71% agreement between Octreoscan and 
immunohistochemistry was obtained. Major causes of discrepancy between these two methods 
include on the one hand false positive SSTRs scintigraphy related to necrotic areas or inflammation 
(often observed in SCLC) [19], in the other the possible role of other SSTR subtypes than types 2A 
and 3 with high affinity for the currently used somatostatin analogues (namely SSTR5, not analyzed 
in this study for technical reason). Moreover, it should be speculated that immunohistochemistry 
may represent a less sensitive method as compared to somatostatin receptor scintigraphy because of 
heterogeneous SSTR distribution in tumour tissues or technical artifacts related to tissue fixation. 
However, we strongly believe that speculating which method is more sensitive or specific is indeed 
useless. In contrast, we encourage the use of immunohistochemistry as a potentially useful adjunct 
to SSTR scintigraphy in lung NETs work-up.  
Despite several cases in our series displayed an aggressive and fatal clinical course even in 
the group of low/intermediate grade tumours, only eight patients of the present series underwent 
biotherapy with somatostatin analogs, therefore limiting the possibility to test the possible value of 
somatostatin receptor immunohistochemistry to predict the clinical response to somatostatin analog 
therapy. This fact, rather than a limit of our investigation, represents the actual clinical picture and 
reflects the lack of robust trials validating the use of  somatostatin analogs in advanced lung NETs.  
In conclusion, our study describes SSTR(s) tissue localization in a very large series of 
aggressive lung NETs with clinicopathologic correlates, and strengthens the concept that the 
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information on SSTR(s) expression at the tissue level in lung NET patients developing clinically 
aggressive disease may improve the clinical approach with somatostatin analog-based diagnostic 
and therapeutic procedures. 
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Table 1. Clinicopathologic features of 218 “clinically aggressive” pulmonary neuroendocrine 
tumours. 
 
TC mets (#24) 
No.a. 
AC (#73) 
No.a. 
LCNEC (#60) 
No.a. 
SCLC (#61) 
No.a. 
Sex 
M 
F 
24  
12 
12 
73  
42 
31 
60  
53 
7 
61  
49 
12 
Age (y) 
Range 
Mean 
Median 
24  
15-78 
48 
49 
73  
11-77 
55 
57 
60  
35-87 
64 
65 
61  
44-84 
65 
66 
Tumour location 
RUL 
RML 
RIL 
LUL 
LIL 
23  
2 
5 
3 
4 
9 
66  
18 
18 
10 
10 
10 
49  
17 
8 
5 
12 
7 
45  
14 
3 
11 
9 
8 
Surgical procedure 
Pneumonectomy 
Bilobectomy 
Lobectomy 
Wedge resection 
Lymph node biopsy 
23  
3 
2 
17 
1 
0 
70  
4 
5 
55 
5 
1 
54  
4 
1 
44 
2 
3 
59  
4 
1 
39 
5 
10 
Parenchymal 
location 
Central 
Peripheral 
Multifocal 
15  
 
9 
4 
2 
36  
 
10 
24 
2 
32  
 
8 
22 
2 
22  
 
12 
10 
0 
Primary tumour size 
(mm) 
<10 
11-29 
>30 
Mean 
23  
 
1 
14 
8 
25 
62  
 
6 
24 
32 
32 
51  
 
2 
16 
33 
42 
47  
 
0 
15 
32 
38 
Ki67 (%) 
Mean 
Range 
18  
3 
0,3-8 
49  
16 
1-70 
39  
70 
30-90 
44  
76 
40-95 
Nodal status 
N0 
N1 
N2-3 
23  
0 
16 
7 
61  
32 
16 
13 
49  
30 
11 
8 
57  
22 
14 
21 
Stage 
1A-1B 
2A-2B 
3A-3B 
4 
23  
0 
9-6 
8-0 
0 
57  
13-17 
6-8 
9-4 
0 
50  
9-14 
1-12 
7-3 
4 
51  
9-11 
3-9 
15-2 
2 
Follow-up (mos) 
Follow up time: 
range 
24  
 
2-175 
72  
 
1-215 
58  
 
1-214 
61  
 
1-120 
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mean 
Mean OS 
47 
n.r 
57 
122 
41 
30 
27 
23 
Disease status 
NED/DOC 
AWD 
DOD 
24  
22 
2 
0 
72  
47 
5 
20 
58  
20 
0 
38 
61  
21 
0 
40 
Site of distant 
metastases 
 Liv: 1 
Lu: 1 
 Adr: 1 
BM: 1 
Bo: 3 
CNS: 1 
Liv: 5 
Lu: 1 
Med: 2 
Ov:1 
Pc:1 
Thy:1 
 Bo: 4 
ChW: 1 
CNS: 1 
Liv: 3 
Lu: 3 
 Adr: 1 
AxLN:1 
Bo: 6 
ChW: 1 
CNS: 7 
Liv: 9 
Lu: 6 
Med: 3 
Abbreviations: TC mets: typical carcinoid with metastases; AC: atypical carcinoid; LCNEC: large 
cell neuroendocrine carcinoma; SCLC: small cell lung carcinoma; No.a.= number of available 
cases; M: male; F: female; RUL: right upper lobe; RML: right medium lobe; RIL: right inferior 
lobe; LUL: left upper lobe; LIL: left inferior lobe; n.a= not applicable; mos= months; NED: not 
evidence of disease; DOC: death of other causes; AWD: alive with disease; DOD: death of disease; 
OS: overall survival; nr: not reached; Adr: adrenal gland; AxLN: axillary lymph node; BM: bone 
marrow; Bo: bone; ChW: chest wall; CNS: central nervous system; Liv: liver; Lu: lung; Med: 
mediastinum; Ov: ovary; Pc: pancreas; Thy: thyroid. 
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Table 2. Correlation between different tumour types and SSTR2A and SSTR3 
immunohistochemical distribution in lung NETs.  
 
SSTR2 
Χ2 p 
SSTR3 
Χ2 p 
SSTR 2 
and/or 3  Χ2 p 
SSTR 2 
and 3  Χ2 p 
pos neg pos neg pos neg pos neg 
Control TC (41) 
TC mets (24) 
14 
17 
27 
7 
0.004 
27 
14 
14 
10 
0.5 
32 
20 
9 
4 
0.6 
9 
11 
32 
13 
0.04 
Control TC (41) 
AC (73) 
14 
37 
27 
36 
0.08 
27 
33 
14 
40 
0.03 
32 
46 
9 
27 
0.06 
9 
24 
32 
49 
0.2 
TC mets (24) 
AC (73) 
17 
37 
7 
36 
0.08 
14 
33 
10 
40 
0.3 
20 
46 
4 
27 
0.09 
11 
24 
13 
49 
0.2 
AC (73) 
LCNEC (60) 
37 
20 
36 
40 
0.04 
33 
20 
40 
40 
0.2 
46 
32 
27 
28 
0.2 
24 
7 
49 
53 
<0.001 
LCNEC (60) 
SCLC (61) 
20 
23 
40 
38 
0.6 
20 
18 
40 
43 
0.7 
32 
34 
28 
27 
0.8 
7 
7 
53 
54 
0.9 
             
TC mets + AC (97) 
LCNEC + SCLC (121) 
54 
43 
43 
78 
0.004 
47 
38 
50 
83 
0.01 
66 
63 
31 
58 
0.02 
35 
14 
62 
107 
<0.001 
 
Abbreviations: TC: typical carcinoid; TC mets: typical carcinoid with; AC: atypical carcinoid; 
LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung carcinoma; WD: well 
differentiated; PD: poorly differentiated. 
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Table 3. Concordance between immunohistochemistry and 
111
In-pentetreotide scintigraphy, 
according to somatostatin receptor type considered. 
 
 SSTR2A SSTR3 SSTR2A or 3 
Overall 
agreement 
64% (18/28) 50% (14/28) 71% (20/28) 
“sensitivity”* 70% 48% 80% 
“specificity”* 71% 57% 42% 
 
FIGURE LEGENDS 
 
Figure 1. Overall survival distribution of 213 “clinically aggressive” lung neuroendocrine tumours. 
 
Figure 2. Distribution of SSTR2A and 3 immunoreactivity in lung NETs. Typical carcinoids with 
metastases (TC mets) showed strong immunohistochemical expression of SSTR2A, with usually a 
diffuse membrane pattern (a) and the higher distribution (b). Atypical carcinoids (AC) showed a 
pattern of staining similar to TC mets (a), but with a lower frequency of positive cases (b). In 
poorly differentiated neuroendocrine carcinomas, such as the large cell type (LCNEC), SSTR2A 
immunohistochemical staining showed a more patchy distribution (a) and the lowest overall 
frequency of positive cases (b). HE: Hematoxylin & Eosin, 200x; SSTR2A: immunoperoxidase for 
somatostatin receptor type 2A, 200x. 
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Figure 1 
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